Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $85,352 | 6 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $82,043 | 1 | $0 (2020) |
| F. Hoffmann-La Roche AG | $3,309 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,182 | 3 | F. Hoffmann-La Roche AG ($1,182) |
| 2021 | $2,128 | 2 | F. Hoffmann-La Roche AG ($2,128) |
| 2020 | $82,043 | 1 | Eli Lilly and Company ($82,043) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $350.95 | Research |
| Study: A PHASE 1B STUDY OF CROVALIMAB IN MANAGEMENT OF ACUTE VOC IN SICKLE CELL DISEASE | ||||||
| 12/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $324.84 | Research |
| Study: A PHASE 1B STUDY OF CROVALIMAB IN MANAGEMENT OF ACUTE VOC IN SICKLE CELL DISEASE | ||||||
| 03/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $505.80 | Research |
| Study: A PHASE 1B STUDY OF CROVALIMAB IN MANAGEMENT OF ACUTE VOC IN SICKLE CELL DISEASE | ||||||
| 10/15/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,478.66 | Research |
| Study: A PHASE 1B STUDY OF CROVALIMAB IN MANAGEMENT OF ACUTE VOC IN SICKLE CELL DISEASE | ||||||
| 06/18/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $648.85 | Research |
| Study: A PHASE 1B STUDY OF CROVALIMAB IN MANAGEMENT OF ACUTE VOC IN SICKLE CELL DISEASE | ||||||
| 08/17/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $82,043.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $82,043 | 1 |
| A PHASE 1B STUDY OF CROVALIMAB IN MANAGEMENT OF ACUTE VOC IN SICKLE CELL DISEASE | F. Hoffmann-La Roche AG | $3,309 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 129 | 141 | $58,352 | $10,913 |
| 2022 | 4 | 230 | 250 | $141,401 | $27,428 |
| 2021 | 5 | 383 | 413 | $228,162 | $45,998 |
| 2020 | 5 | 394 | 424 | $232,701 | $43,048 |
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 38 | 38 | $35,530 | $6,485 | 18.3% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 34 | 36 | $18,936 | $3,956 | 20.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 57 | 67 | $3,886 | $472.56 | 12.2% |
| 99285 | Emergency department visit for life threatening or functioning severity | Facility | 2022 | 105 | 106 | $99,110 | $19,705 | 19.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 19 | 19 | $25,213 | $4,449 | 17.6% |
| 99284 | Emergency department visit for problem of high severity | Facility | 2022 | 21 | 21 | $11,046 | $2,491 | 22.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 85 | 104 | $6,032 | $782.70 | 13.0% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2021 | 162 | 164 | $153,340 | $31,411 | 20.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 26 | 26 | $34,502 | $6,407 | 18.6% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 47 | 47 | $24,722 | $5,534 | 22.4% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2021 | 22 | 22 | $6,666 | $1,521 | 22.8% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 126 | 154 | $8,932 | $1,126 | 12.6% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2020 | 171 | 173 | $161,755 | $30,060 | 18.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 28 | 28 | $37,156 | $6,808 | 18.3% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2020 | 32 | 32 | $16,832 | $3,471 | 20.6% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2020 | 19 | 24 | $7,272 | $1,430 | 19.7% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 144 | 167 | $9,686 | $1,279 | 13.2% |
About Dr. Jonathan Schimmel, MD
Dr. Jonathan Schimmel, MD is a Emergency Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2013. The National Provider Identifier (NPI) number assigned to this provider is 1215374368.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Schimmel, MD has received a total of $85,352 in payments from pharmaceutical and medical device companies, with $1,182 received in 2022. These payments were reported across 6 transactions from 2 companies. The most common payment nature is "" ($85,352).
As a Medicare-enrolled provider, Schimmel has provided services to 1,136 Medicare beneficiaries, totaling 1,228 services with total Medicare billing of $127,388. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Practice Information
- Specialty Emergency Medicine
- Other Specialties Emergency Medicine, Medical Toxicology
- Location New York, NY
- Active Since 05/30/2013
- Last Updated 06/14/2022
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1215374368
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in New York
Benjamin Abella, Md, MD
Emergency Medicine — Payments: $187,938
Dr. Sohan Parekh, M.d, M.D
Emergency Medicine — Payments: $156,713
Dr. Leroy Nickles, M.d, M.D
Emergency Medicine — Payments: $64,172
Bret Nelson, Md, MD
Emergency Medicine — Payments: $63,058
Yves Duroseau, Md, MD
Emergency Medicine — Payments: $46,664
Jeffrey Goldstein, D.o, D.O
Emergency Medicine — Payments: $26,302